Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular eve...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for the Advancement of Science
2020
|
| _version_ | 1797106465497939968 |
|---|---|
| author | Bovijn, J Krebs, K Chen, C-Y Boxall, R Censin, JC Ferreira, T Pulit, SL Glastonbury, CA Millwood, IY Lin, K Chen, Z Walters, RG Mägi, R Neale, BM Neale, BM Lindgren, CM Holmes, MV |
| author_facet | Bovijn, J Krebs, K Chen, C-Y Boxall, R Censin, JC Ferreira, T Pulit, SL Glastonbury, CA Millwood, IY Lin, K Chen, Z Walters, RG Mägi, R Neale, BM Neale, BM Lindgren, CM Holmes, MV |
| author_sort | Bovijn, J |
| collection | OXFORD |
| description | Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular events, and regulatory agencies have issued marketing authorizations with warnings of cardiovascular disease. Here, we meta-analyze published and unpublished cardiovascular outcome trial data of romosozumab and investigate whether genetic variants that mimic therapeutic inhibition of sclerostin are associated with higher risk of cardiovascular disease. Meta-analysis of up to three RCTs indicated a probable higher risk of cardiovascular events with romosozumab. Scaled to the equivalent dose of romosozumab (210 milligrams per month; 0.09 grams per square centimeter of higher bone mineral density), the SOST genetic variants were associated with lower risk of fracture and osteoporosis (commensurate with the therapeutic effect of romosozumab) and with a higher risk of myocardial infarction and/or coronary revascularization and major adverse cardiovascular events. The same variants were also associated with increased risk of type 2 diabetes mellitus and higher systolic blood pressure and central adiposity. Together, our findings indicate that inhibition of sclerostin may elevate cardiovascular risk, warranting a rigorous evaluation of the cardiovascular safety of romosozumab and other sclerostin inhibitors. |
| first_indexed | 2024-03-07T07:02:53Z |
| format | Journal article |
| id | oxford-uuid:338eeda8-7de9-41e1-ba02-77c1740fe263 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:02:53Z |
| publishDate | 2020 |
| publisher | American Association for the Advancement of Science |
| record_format | dspace |
| spelling | oxford-uuid:338eeda8-7de9-41e1-ba02-77c1740fe2632022-04-05T13:58:59ZEvaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human geneticsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:338eeda8-7de9-41e1-ba02-77c1740fe263EnglishSymplectic ElementsAmerican Association for the Advancement of Science2020Bovijn, JKrebs, KChen, C-YBoxall, RCensin, JCFerreira, TPulit, SLGlastonbury, CAMillwood, IYLin, KChen, ZWalters, RGMägi, RNeale, BMNeale, BMLindgren, CMHolmes, MVInhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular events, and regulatory agencies have issued marketing authorizations with warnings of cardiovascular disease. Here, we meta-analyze published and unpublished cardiovascular outcome trial data of romosozumab and investigate whether genetic variants that mimic therapeutic inhibition of sclerostin are associated with higher risk of cardiovascular disease. Meta-analysis of up to three RCTs indicated a probable higher risk of cardiovascular events with romosozumab. Scaled to the equivalent dose of romosozumab (210 milligrams per month; 0.09 grams per square centimeter of higher bone mineral density), the SOST genetic variants were associated with lower risk of fracture and osteoporosis (commensurate with the therapeutic effect of romosozumab) and with a higher risk of myocardial infarction and/or coronary revascularization and major adverse cardiovascular events. The same variants were also associated with increased risk of type 2 diabetes mellitus and higher systolic blood pressure and central adiposity. Together, our findings indicate that inhibition of sclerostin may elevate cardiovascular risk, warranting a rigorous evaluation of the cardiovascular safety of romosozumab and other sclerostin inhibitors. |
| spellingShingle | Bovijn, J Krebs, K Chen, C-Y Boxall, R Censin, JC Ferreira, T Pulit, SL Glastonbury, CA Millwood, IY Lin, K Chen, Z Walters, RG Mägi, R Neale, BM Neale, BM Lindgren, CM Holmes, MV Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics |
| title | Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics |
| title_full | Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics |
| title_fullStr | Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics |
| title_full_unstemmed | Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics |
| title_short | Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics |
| title_sort | evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta analysis of clinical trials and human genetics |
| work_keys_str_mv | AT bovijnj evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT krebsk evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT chency evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT boxallr evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT censinjc evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT ferreirat evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT pulitsl evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT glastonburyca evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT millwoodiy evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT link evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT chenz evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT waltersrg evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT magir evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT nealebm evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT nealebm evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT lindgrencm evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT holmesmv evaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics |